Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

Bar‐Or, Amit; Grove, Richard; Austin, Daren; M. Tolson, Jerry; VanMeter, Susan; Lewis, Eric; J. Derosier, Frederick; C. Lopez, Monica; Kavanagh, Sarah; Miller, Aaron; Soelberg Sørensen, Per

doi:10.1212/wnl.0000000000005516

Public

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

Published in Neurology • Apr 25, 2018

Authors:

Amit Bar‐Or

Richard Grove

Daren Austin

Abstract

OBJECTIVE: To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS). METHODS: Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks, ofatum...

Subject

Relapsing remitting

Ofatumumab

Multiple sclerosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!